SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 55.48-8.8%3:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (7410)12/4/2002 1:49:22 PM
From: Biomaven  Read Replies (1) of 52153
 
Here's an interesting (but small) study on the whole thiomersal/vaccine issue. Very reassuring in my view (except to the trial lawyers):

Mercury concentrations and metabolism in infants receiving vaccines containing thiomersal: a descriptive study

Michael E Pichichero, Elsa Cernichiari, Joseph Lopreiato, John Treanor

Departments of Microbiology/Immunology (Prof M E Pichichero MD), Environmental Medicine (E Cernichiari), and Medicine (J Treanor MD), University of Rochester, Rochester, New York, NY, USA; and National Naval Medical Center, Bethesda, MD (J Lopreiato MD)

Correspondence to: Dr Michael E Pichichero, Department of Microbiology/Immunology, University of Rochester Medical Center, 601 Elmwood Avenue, Box 672, Rochester, NY 14642, USA (e-mail:michael_pichichero@urmc.rochester.edu) Summary
Introduction
Methods
Results
Discussion
References

Summary

Background Thiomersal is a preservative containing small amounts of ethylmercury that is used in routine vaccines for infants and children. The effect of
vaccines containing thiomersal on concentrations of mercury in infants' blood has not been extensively assessed, and the metabolism of ethylmercury in infants is unknown. We aimed to measure concentrations of mercury in blood, urine, and stools of infants who received such vaccines. Methods 40 full-term infants aged 6 months and younger were given vaccines that contained thiomersal (diptheria-tetanus-acellular pertussis vaccine, hepatitis B vaccine, and in some children Haemophilus influenzae type b vaccine). 21 control infants received thiomersal-free vaccines. We obtained samples of blood, urine, and stools 3-28 days after vaccination. Total mercury (organic and inorganic) in the samples was measured by cold vapour atomic absorption. Findings Mean mercury doses in infants exposed to thiomersal were 45·6 µg (range 37·5-62·5) for 2-month-olds and 111·3 µg (range 87·5-175·0) for 6-month- olds. Blood mercury in thiomersal-exposed 2-month-olds ranged from less than 3·75 to 20·55 nmol/L (parts per billion); in 6-month-olds all values were lower than 7·50 nmol/L. Only one of 15 blood samples from controls contained quantifiable mercury. Concentrations of mercury were low in urine after vaccination but were high in stools of thiomersal-exposed 2-month-olds (mean 82 ng/g dry weight) and in 6-month-olds (mean 58 ng/g dry weight). Estimated blood half-life of ethylmercury was 7 days (95% CI 4-10 days). Interpretation Administration of vaccines containing thiomersal does not seem to raise blood concentrations of mercury above safe values in infants. Ethylmercury seems to be eliminated from blood rapidly via the stools after parenteral administration of thiomersal in vaccines. Lancet 2002; 360: 1737-41


Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext